Literature DB >> 8200618

The IGF axis in the prostate.

P Cohen1, D M Peehl, R G Rosenfeld.   

Abstract

The insulin-like growth factor (IGF) axis is a multi-component network of molecules involved in the regulation of cell growth. The axis includes two major ligands, (IGF-I and IGF-II), cell surface receptors, (the type I IGF receptor family as well as the type II IGF receptor), a family of high affinity binding proteins which regulate IGF availability to the receptors, (the IGFBPs), and a group of IGFBP proteases which cleave IGFBBPs and modulate IGF action. Human seminal plasma contains IGF-I and -II, IGFBP-2 and -4, as well as IGFBP-3 fragments and IGFBP-3 protease activity. A prostatic source for these IGF-axis molecules is likely. We have demonstrated the human prostate to contain all the elements of a functional IGF system. Prostate fibroblasts in primary culture (PC-F) express mRNA for IGF-II and produce IGF-II peptide in biologically active concentrations. This IGF-II appears to be of a high molecular weight (15 kD) species. Prostate epithelial cells in primary culture (PC-E) express the type I IGF receptor. These cells also produce IGFBP-2 and -4, (on both mRNA and peptide levels), while PC-F secrete IGFBP-2, -3 and -4. PC-E are exquisitely sensitive to the mitogenic effects of IGFs. Finally, prostate specific antigen (PSA), secreted from PC- and found in seminal plasma, can function as a potent IGFBP-3 protease. This IGFBP-3 protease activity can remove the inhibitory effects of IGFBP-3 on IGF-I induced PC-3 growth.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8200618     DOI: 10.1055/s-2007-1000777

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  26 in total

Review 1.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

Review 2.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

3.  NF-κB gene signature predicts prostate cancer progression.

Authors:  Renjie Jin; Yajun Yi; Fiona E Yull; Timothy S Blackwell; Peter E Clark; Tatsuki Koyama; Joseph A Smith; Robert J Matusik
Journal:  Cancer Res       Date:  2014-03-31       Impact factor: 12.701

Review 4.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

Review 5.  Regulation of prostate cell growth by the insulin-like growth factor binding proteins and their proteases.

Authors:  S E Nunn; T B Gibson; R Rajah; P Cohen
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

6.  Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice.

Authors:  J DiGiovanni; K Kiguchi; A Frijhoff; E Wilker; D K Bol; L Beltrán; S Moats; A Ramirez; J Jorcano; C Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

Review 7.  Mechanisms of the development of androgen independence in prostate cancer.

Authors:  Alan So; Martin Gleave; Antonio Hurtado-Col; Colleen Nelson
Journal:  World J Urol       Date:  2005-01-27       Impact factor: 4.226

Review 8.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

Review 9.  Diabetes and benign prostatic hyperplasia: emerging clinical connections.

Authors:  Aruna V Sarma; J Kellogg Parsons
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

10.  Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.

Authors:  Marian L Neuhouser; Jeannette Schenk; Yoon Ju Song; Catherine M Tangen; Phyllis J Goodman; Michael Pollak; David F Penson; Ian M Thompson; Alan R Kristal
Journal:  Prostate       Date:  2008-09-15       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.